癌症研究
肺癌
KEAP1型
突变体
肺
放射治疗
效应器
生物
医学
免疫学
转录因子
基因
肿瘤科
遗传学
内科学
作者
Pranavi Koppula,Guang Lei,Yilei Zhang,Yizhong Yan,Chao Mao,Lavanya Kondiparthi,Jiejun Shi,Xiaoguang Liu,Amber Horbath,Molina Das,Wei Li,Masha V. Poyurovsky,Kellen L. Olszewski,Boyi Gan
标识
DOI:10.1038/s41467-022-29905-1
摘要
Targeting ferroptosis, a unique cell death modality triggered by unrestricted lipid peroxidation, in cancer therapy is hindered by our incomplete understanding of ferroptosis mechanisms under specific cancer genetic contexts. KEAP1 (kelch-like ECH associated protein 1) is frequently mutated or inactivated in lung cancers, and KEAP1 mutant lung cancers are refractory to most therapies, including radiotherapy. In this study, we identify ferroptosis suppressor protein 1 (FSP1, also known as AIFM2) as a transcriptional target of nuclear factor erythroid 2-related factor 2 (NRF2) and reveal that the ubiquinone (CoQ)-FSP1 axis mediates ferroptosis- and radiation- resistance in KEAP1 deficient lung cancer cells. We further show that pharmacological inhibition of the CoQ-FSP1 axis sensitizes KEAP1 deficient lung cancer cells or patient-derived xenograft tumors to radiation through inducing ferroptosis. Together, our study identifies CoQ-FSP1 as a key downstream effector of KEAP1-NRF2 pathway and as a potential therapeutic target for treating KEAP1 mutant lung cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI